Volume : 12, Issue : 03, March – 2025

Title:

FEATURES, EVALUATION, AND TREATMENT OF COVID 19

Authors :

Somnath S.Aandhale, Priyanka R.Nagargoje, Dr.Kumar P.Surwase

Abstract :

This study investigates the clinical presentation, transmission, laboratory findings, and treatment outcomes of COVID-19 patients. Data was collected from hospital records, government health portals, and published literature, focusing on patients confirmed COVID-19 positive by RT-PCR. The study includes all age groups and genders, while excluding suspected cases without confirmatory test results and patients with incomplete data. Data analysis categorized patients based on age, gender, symptoms, test types, treatment methods, and outcomes, with comparisons made between mild, moderate, and severe cases.
Common symptoms identified were fever, dry cough, fatigue, sore throat, and loss of taste/smell. Severe cases included pneumonia, ARDS, thrombosis, and multi-organ failure. Transmission occurs primarily through respiratory droplets and aerosols, with an incubation period of 2-14 days. Laboratory findings showed decreased lymphocyte count, elevated inflammation markers (CRP, D-dimer, ferritin), and positive PCR or antigen tests. Imaging revealed bilateral ground-glass opacities on chest X-ray/CT.Most patients, especially those with mild to moderate cases, recovered without hospitalization. Complications included pneumonia, ARDS, blood clots, and long COVID. Mortality was higher among elderly patients and those with comorbidities. The findings underscore the importance of preventive measures such as hand hygiene, social distancing, and quarantine to control the spread of the virus.

Cite This Article:

1. Amutai, M. A. (2021). The coronavirus disease 2019 (COVID-19) outbreak: Challenges to pediatric dentistry. Journal of Research in Medical and Dental Science, 9, 116–121.
2. Chan, J. F., Yuan, S., Kok, K. H., et al. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. The Lancet, 395, 514–523. https://doi.org/10.1016/S0140-6736(20)30154-9
3. Chowdhury, S. D., & Oommen, A. M. (2020). Epidemiology of COVID-19. Journal of Digestive Endoscopy, 11(1), 3–7.
4. Arons, M. M., Hatfield, K. M., Reddy, S. C., et al. (2020). Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. New England Journal of Medicine, 382, 2081–2090. https://doi.org/10.1056/NEJMoa2008457
5. Wang, D., Hu, B., Hu, C., et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585
6. World Health Organization. (2020). Estimating mortality from COVID-19: Scientific brief. https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Mortality-2020.1
7. Ioannidis, J. P. A. (2021). Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations. European Journal of Clinical Investigation, 51(5), e13554. https://doi.org/10.1111/eci.13554
8. Linton, N. M., Kobayashi, T., & Yang, Y. (2020). Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: A statistical analysis of publicly available case data. Journal of Clinical Medicine, 9(2), 538. https://doi.org/10.3390/jcm9020538
9. Shkolnikov, V. M., Acosta, R. J., et al. (2021). Excess deaths associated with COVID-19 pandemic in 2020: Age and sex disaggregated time series analysis in 29 high-income countries. BMJ, 373, n1137. https://doi.org/10.1136/bmj.n1137
10. Zhang, J., Litvinova, M., Wang, W., et al. (2020). Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: A descriptive and modelling study. The Lancet Infectious Diseases, 20(7), 793–802. https://doi.org/10.1016/S1473-3099(20)30230-9
11. Cascella, M., Rajnik, M., Aleem, A., et al. (2021). Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK554776/
12. Güner, R., Hasanoglu, I., & Aktas, F. (2020). COVID-19: Prevention and control measures in the community. Turkish Journal of Medical Sciences, 50(SI-1), 571–577. https://doi.org/10.3906/sag-2004-146
13. World Health Organization. (2020, December). Mask use in the context of COVID-19: Interim guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC_Masks-2020.4
14. Graham, M. S., Sudre, C. H., May, A., et al. (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study. The Lancet Public Health, 6(5), e335–e345. https://doi.org/10.1016/S2468-2667(21)00055-4
15. World Health Organization. (2023, March). Statement on SARS-CoV-2 variants of concern and interest. https://www.who.int
16. Adjei, S., Hong, K., Molinari, N. M., et al. (2022). Mortality risk among patients hospitalized primarily for COVID-19 during the immunity and period of infectivity: United States, April 2020–June 2022. MMWR. Morbidity and Mortality Weekly Report, 71(37), 1182–1189. https://doi.org/10.15585/mmwr.mm7137e2
17. Raj, U. (2020). Indian education system in fight against COVID-19 pandemic. International Journal of Creative Research Thoughts (IJCRT), 8, July Issue.
18. To, K. K. W., Tsang, O. T. Y., Leung, W. S., et al. (2020). Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. The Lancet Infectious Diseases, 20(5), 565–574. https://doi.org/10.1016/S1473-3099(20)30196-1
19. Novavax. (2023). Our Matrix-M™ adjuvant technology. Retrieved October 23, 2023, from https://www.novavax.com/
20. World Health Organization Strategic Advisory Group of Experts on Immunization (SAGE). (2021). Interim policy recommendations for the use of the Bharat Biotech BBV152 COVAXIN vaccine.
21. Ministry of Health and Family Welfare. (2021, January 1). Fact sheet for vaccine recipients and caregivers: Restricted use of Covaxin™ under clinical trial mode. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/en/FactsheetofChAdSerum.pdf
22. World Health Organization. (2020). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
23. Zhou, P., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579, 270–273. https://doi.org/10.1038/s41586-020-2012-7
24. Guan, W. J., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382(18), 1708–1720. https://doi.org/10.1056/NEJMoa2002032
25. Corman, V. M., et al. (2020). Detection of 2019 novel coronavirus by RT-PCR. Eurosurveillance, 25(3), 2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045
26. Beigel, J. H., et al. (2020). Remdesivir for the treatment of COVID-19. New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764
27. RECOVERY Collaborative Group. (2020). Dexamethasone in hospitalized patients with COVID-19. New England Journal of Medicine, 384(8), 693–704. https://doi.org/10.1056/NEJMoa2021436
28. Polack, F. P., et al. (2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577
29. Xiong, J., et al. (2020). Impact of COVID-19 pandemic on mental health in the general population: A systematic review. Journal of Affective Disorders, 277, 55–64. https://doi.org/10.1016/j.jad.2020.08.001
30. Bambra, C., et al. (2020). The COVID-19 pandemic and health inequalities. Journal of Epidemiology and Community Health, 74(11), 964–968. https://doi.org/10.1136/jech-2020-214401
31. National Institutes of Health. (2024). COVID-19 treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/
32. RECOVERY Collaborative Group. (2021). Dexamethasone in hospitalized patients with COVID-19. New England Journal of Medicine, 384(8), 693–704. https://doi.org/10.1056/NEJMoa2021436